LUMOS-DIAGNOSTICS
6.10.2020 23:52:11 CEST | Business Wire | Press release
Lumos Diagnostics , a rapid point-of-care diagnostics company, has closed an oversubscribed AU$25 million pre-IPO capital raise, ahead of an anticipated 2021 Australian Securities Exchange (ASX) listing.
The funding will enable Lumos, headquartered in Melbourne, to continue to build its high-growth rapid diagnostics business in the U.S., including expanding manufacturing operations in California and Florida and continuing commercial growth of its FebriDx® product, a world-first finger prick blood test that can indicate if a person has a bacterial or viral infection within 10 minutes.
The capital was raised from a combination of institutional funds, including Perennial Value and Ellerston Capital, and sophisticated investors, many of whom have backed Lumos through previous capital raises. It follows on from a successful Series A raise in early 2020, led by Planet Innovation , a Melbourne-based healthcare innovation company.
“Lumos has built a strong foundation over the past few years, and this funding will enable us to accelerate our growth plan,” said Sam Lanyon, executive chair of Lumos Diagnostics. “We’re delighted that investors recognize how unique Lumos is with its suite of rapid diagnostic digital solutions coupled with high-impact and globally relevant proprietary products such as FebriDx.”
David Keelan, Portfolio Manager at Ellerston Capital and a first-time Lumos investor, said: “I’m really excited by Lumos’s potential. Rapid diagnostics is a developing sector internationally, and to have a really strong and growing service business, complemented by a product business with huge potential – it was too good an investment to pass up.”
Ryan Sohn, Deputy Portfolio Manager at Perennial Value, was introduced to Lumos Diagnostics through Planet Innovation (PI), where he is also an investor. “Through PI, I’ve been able to track Lumos’s substantial growth over the past few years. It’s a company with great ambition and a great team behind it, and I’m excited to be a part of this next phase of growth as it prepares for an IPO next year,” Ryan said.
While many businesses have been negatively impacted by the devastating global impacts of the COVID-19 crisis, Lumos was well positioned to quickly respond and has subsequently experienced growth across both its service and product businesses. On the service side, Lumos has secured several contracts to develop and manufacture next generation rapid SARS-CoV-2 tests. On the product side, the UK’s National Institute of Health Research (NIHR) has demonstrated real-world use of the FebriDx test as a frontline triage tool to help healthcare workers manage suspected COVID-19 infected patients. The FebriDx test was featured in a UK Medtech Innovation Briefing (MIB) , addressing the impact that the FebriDx test can have on the concurrent COVID-19 pandemic and antimicrobial resistance global health crises. Also, FebriDx may be used as an important risk assessment tool for safe workplaces and is currently being piloted in aged care and other professional use settings continuing to operate during the pandemic.
Robert Sambursky, MD, president and chief executive officer for Lumos Diagnostics, said the capital raise would enable Lumos to expand its commercial operations dedicated to both the continued development of rapid point-of-care diagnostics and meet the need for innovative testing solutions to help address the global COVID-19 pandemic.
“The unique ability of the FebriDx test to identify patients as viral or bacterial within 10 minutes helps guide clinical decision making – whether that is isolation for those identified as having a virus, antibiotic prescriptions for bacterial infections, or simply reassurance that an infection is not present. These actionable results make FebriDx the ideal front-line triage test for patients presenting with acute respiratory illness symptoms (sore throat, cough, shortness of breath) consistent with COVID-19 and an ideal tool for rapid deployment in any future pandemics,” Sambursky said.
While FebriDx is not yet commercially available in the U.S., Lumos Diagnostics has both ongoing and historic prospective, multicenter U.S. clinical trials and anticipates U.S. Food and Drug Administration (FDA) clearance.
Blackpeak Capital acted as Financial Advisor to Lumos and Joint Lead Manager for the raising alongside Canaccord Genuity.
About Lumos Diagnostics
Lumos Diagnostics specializes in rapid, cost-effective and complete point-of-care (POC) diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases with unmet diagnostic needs.
Lumos’s current portfolio of tests includes:
- FebriDx®, an all-in-one, disposable, 10-minute, fingerstick blood test that differentiates viral from bacterial acute respiratory infections (ARI).
- COV-ID™; the Diagnostic Kit (Colloidal Gold) for IgG/IgM Antibody to SARS-CoV-2, a rapid and easy-to-use serology test for the qualitative detection of antibodies to SARS-CoV-2 virus in patients suspected of a history of COVID-19 infection.
Both the FebriDx and COV-ID tests are CE marked for sale in Europe. FebriDx is also registered or licensed with the following other health authorities: Health Canada, Australia TGA, Saudi Arabia FDA, Pakistan DRAP, Singapore HSA, and Malaysia MoH. COV-ID is available in specific global markets in compliance with country requirements. The FebriDx test has not received U.S. FDA clearance and is not commercially available in the United States. For more information on Lumos Diagnostics, visit lumosdiagnostics.com , and for more information on FebriDx, visit febridx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006006109/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ATLAS Infrastructure Invests in H2O America, Backs Long-Term Growth Strategy10.3.2026 18:29:00 CET | Press release
ATLAS anchors H2O America’s equity raise and establishes new substantial shareholdingUpsized transaction highlights strong market support for H2O’s long-term strategy and sector leading growth outlookH2O’s organic growth fully equity funded into 20281 ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing funds on behalf of long-term infrastructure clients. Following the recent equity placement, ATLAS’s actively managed accounts hold ~10.8% voting and economic interest in H2O America (“H2O”). ATLAS was pleased to support H2Os long‑term strategy to invest in local water and wastewater utility operations through our participation in the recent equity raise. ATLAS recognises the disciplined approach from H2O management which focuses on organic investment in existing businesses alongside targeted and accretive transactions such as the acquisition of Quadvest which materially expands H2O’s regulated water footprint in a premium high‑growth jurisdiction
TIXiMED Announces Promising Preclinical Data: Oral TIX100 Prevents Weight Regain After GLP-1 Cessation in Obesity Model10.3.2026 18:22:00 CET | Press release
TIX100 prevented weight regain in mice after semaglutide discontinuation Supports potential role as oral weight maintenance therapy following GLP-1 Receptor Agonist (GLP-1) treatment, addressing a major challenge in long-term obesity management TIXiMED, Inc., a clinical-stage pharmaceutical company developing a novel oral therapy targeting thioredoxin-interacting protein (TXNIP) for diabetes and metabolic disorders, is pleased to highlight new research by investigators at the University of Alabama at Birmingham (UAB) Comprehensive Diabetes Center. The study demonstrates that its oral compound, TIX100, effectively prevents weight rebound following discontinuation of GLP-1 treatment in a mouse model of diet-induced obesity. In the study, mice treated with semaglutide experienced significant weight loss of over 13% body weight during a 2-week treatment period while continuing a high-fat diet. Upon discontinuation of semaglutide, untreated mice rapidly regained 14% of their body weight, mi
Svante and Integrated Packaging Company Advance U.S. Biogenic CDR Project to Feasibility10.3.2026 14:57:00 CET | Press release
The bioenergy with carbon capture (BECCS) project aims to remove more than 500,000 tonnes per year of biogenic CO2 emissions from a U.S. paper mill’s recovery boiler Svante Development Inc. is co-investing to advance the project The project will generate high-quality carbon dioxide removal (CDR) credits to market to Voluntary Carbon Market (VCM) buyers. Svante Technologies Inc. (“Svante”) announced today that its bioenergy with carbon capture and storage (BECCS) project at a paper mill in the Southeast U.S. has progressed to the feasibility study phase. The project is being developed in partnership with an integrated sustainable packaging company, following an extensive screening and pre-feasibility study conducted across several of the partner’s mills. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310319382/en/ During the feasibility study phase, the companies will complete further engineering and design activities, cos
Forbes 40th Annual World’s Billionaires List10.3.2026 14:43:00 CET | Press release
Elon Musk Is World’s Richest Person Ever Recorded Forbes releases its 40th-annual World’s Billionaireslist, the definitive ranking of the planet’s richest people. Wealth surged to unprecedented levels over the past year, with fortunes climbing at a record pace. This year’s list features 3,428 billionaires, the most since the list’s inception in 1987. The world’s wealthiest people are worth a record $20.1 trillion combined, up from $16.1 trillion in 2025. Elon Musktops the Billionaires list for the second year in a row and is the richest person ever recorded, worth an estimated $839 billion. His net worth skyrocketed by half of a trillion dollars from last year, thanks to a rise in the value of Tesla, and SpaceX which is aiming to go public in 2026. Musk is the first person ever recorded to reach the $800 billion mark, as he moves toward becoming the world’s first trillionaire. “It’s the year of the billionaire,” said Chase Peterson-Withorn, Forbes Senior Editor, Wealth. “The planet add
Adtran sets intra-data center benchmark with all-new ultra-low-power LiteWave800™ LPO module10.3.2026 14:00:00 CET | Press release
News summary: AI clusters and GPU fabrics demand massive capacity, yet traditional 800G optics increase energy consumption, heat and cost burdens Adtran’s LiteWave800™ introduces a new class of ultra-low-power, low-latency DR8 LPO modules built on a fully re-engineered design Breakthrough energy efficiency of 1pJ/bit enables greener, scalable intra-data center links for next-generation AI and cloud workloads Adtran today launched LiteWave800™, an ultra‑low‑power 800Gbit/s DR8 linear pluggable optics (LPO) module engineered to help data centers address the power, latency, thermal and bandwidth demands of modern AI and machine-learning (ML) workloads. As GPU clusters grow and short-reach links scale across dense server racks, operators need 800Gbit/s optics that deliver higher capacity within strict power and cooling limits. LiteWave800™ answers this challenge with a fully re-engineered architecture that significantly reduces energy consumption. Operating at just 1pJ/bit and consuming on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom